Cite
Capeding MR, Alberto E, Feser J, et al. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. Vaccine X. 2020;6:100074doi: 10.1016/j.jvacx.2020.100074.
Capeding, M. R., Alberto, E., Feser, J., Mooney, J., Tang, Y., Audet, S. A., Beeler, J. A., Ellison, D. W., Zhang, L., Letson, G. W., Neuzil, K. M., & Marfin, A. A. (2020). Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. Vaccine: X, 6100074. https://doi.org/10.1016/j.jvacx.2020.100074
Capeding, Maria Rosario, et al. "Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial." Vaccine: X vol. 6 (2020): 100074. doi: https://doi.org/10.1016/j.jvacx.2020.100074
Capeding MR, Alberto E, Feser J, Mooney J, Tang Y, Audet SA, Beeler JA, Ellison DW, Zhang L, Letson GW, Neuzil KM, Marfin AA. Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9-12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial. Vaccine X. 2020 Aug 14;6:100074. doi: 10.1016/j.jvacx.2020.100074. eCollection 2020 Dec 11. PMID: 33005887; PMCID: PMC7509462.
Copy
Download .nbib